Pink SheetThe European Medicines Agency was this week deciding whether the planned EU marketing authorization applications (MAAs) for three investigational products deserved accelerated assessments – apitegroma
ScripNot even two months into the new year and some of the expected biggest-earning new drugs of 2025 have already been approved. An updated analysis conducted by Scrip and Evaluate Pharma of drugs expec
ScripBiotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b
Scrip2024 got off to a good start for Vertex with positive Phase III studies of its novel pain therapy, suzetrigine (then known as VX-548), reported in January. The non-opioid, oral selective inhibitor of